Novo Nordisk
NVO
#111
Rank
HK$1.398 T
Marketcap
HK$317.35
Share price
-1.55%
Change (1 day)
-16.92%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): HK$30.88

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is HK$30.95. In 2025 the company made an earnings per share (EPS) of HK$27.85 an increase over its 2024 EPS that were of HK$25.68.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$30.8810.87%
2025HK$27.858.48%
2024HK$25.68
2016HK$8.75

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$5.57-82.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$242.32 682.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$15.54-49.81%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
HK$35.46 14.55%๐Ÿ‡บ๐Ÿ‡ธ USA